Veno arterial extracorporeal membrane oxygenation (VA ECMO) is used, for cardiogenic shock, refractory cardiac arrest and post cardiotomy cardiac failure. Bleeding is frequent complications during VA ECMO and is associated with increased mortality. The aim of our study was to identify early factors associated with major bleeding in patients supported by VA ECMO
Study Type
OBSERVATIONAL
Enrollment
278
ECMO installation
CHU Dijon Bourgogne
Dijon, France
Rate of major hemorrhagic episodes defined as follows: loss of over 2g dl-1 of hemoglobin in 24 h, bleeding rate over 20 ml kg-1 day-1 or blood transfusion over 10 ml kg-1 day-1
Our main objective was to evaluate risk factors independently associated with major hemorrhagic episode. We collected patient characteristics at the start of VA ECMO: age, gender, anthropometric information, medical history and chronic treatments. We also calculated SOFA and APACHE II scores on the day of VA ECMO implementation. We noted the indication for VA ECMO, any pre-cannulation treatments (fibrinolysis, aspirin, heparin), where VA ECMO was inserted and whether or not an intra-aortic balloon pump was present. With regard to various complications, we collected the quantity of delivered blood products , the site of bleeding initial temperature. The biological data were collected at initiation of VA ECMO.
Time frame: Through study completion, an average of 10 years
Rate of mortality
Time frame: 30 day
Duration of life support
Time frame: Through study completion, an average of 10 years
Length of stay
Time frame: Through study completion, an average of 10 years
Ischemic and thrombotic complications
Time frame: Through study completion, an average of 10 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.